세계의 임상시험 이미징 시장 예측(-2029년) : 소프트웨어 및 서비스별, 모달리티별, 치료 영역별, 최종사용자별

According to projections, the global clinical trial imaging market is expected to grow at a compound annual growth rate (CAGR) of 7.8%, from USD 1.42 billion in 2024 to USD 2.07 billion by 2029. Factors driving the market's growth include the biotechnology and pharmaceutical industries' expansion, the rise in R&D spending, and the number of Contract Research Organizations (CROs). However, the primary factors impeding the market's growth during the projection period are the high cost of clinical trials and the high implementation cost of imaging systems.

"By service & software, the service sector had the fastest growth rate in the clinical trial imaging market throughout the projected period."

Based on type, services and software comprise the clinical trial imaging industry. In the clinical trial imaging market in 2023, the service sector had the fastest growth rate. The operational imaging services, reader analysis services, system & technical support services, and trial design consulting services are further subdivided under the services sector based on type. Growing R&D expenditures, an increase in clinical trials, and the need for novel illness treatments and diagnostics are the main factors contributing to this segment's growth.

"Medical device manufacturers segment accounted for the highest CAGR."

The pharmaceutical and biotechnology firms, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users are the segments of the clinical trial imaging market based on end user. The segment with the highest growth rate in 2023 was medical device manufacturers. This can be explained by the fact that the major growth drivers of the medical device manufacturers segment are the rising R&D expenditures and R&D activity by medical device manufacturers as well as the growing medical device market.

"Asia Pacific: The fastest-growing region clinical trial imaging market."

The markets for clinical trial imaging across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa and GCC countries comprise the global market. Over the course of the projection period, the Asia Pacific area is expected to record the greatest CAGR. The large number of SMEs, the presence of a large treatment-naive population for clinical trials, less-stringent regulations governing the use of animals in clinical research, the availability of local CROs with strong regulatory and linguistic understanding, the presence of highly qualified researchers, and the low cost of clinical trials are the major factors driving the R&D sector. These drivers driving the market's expansion are therefore due to the rise in R&D expenditures and the increasing trend of outsourcing pharmaceutical research to developing Asian countries.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa - 4%

Prominent companies are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).

Research Coverage:

This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical trial imaging market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical trial imaging market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the clinical trial imaging market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical trial imaging market.
• Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US), among others in the clinical clinical trial imaging market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
    • 2.2.1.2 Objectives of secondary research
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Objectives of primary research
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primaries
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Company revenue estimation approach
    • 2.3.1.2 Company presentations and primary interviews
    • 2.3.1.3 Growth forecasts
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW
• 4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2024 VS. 2029
• 4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2024 VS. 2029
• 4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029
• 4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2024 VS. 2029
• 4.6 CLINICAL TRIAL IMAGING MARKET: REGIONAL GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing R&D spending in pharmaceutical and biotechnology companies
    • 5.2.1.2 Rising number of clinical trials in medical research
    • 5.2.1.3 Growth in pharmaceutical and biotechnology industries
    • 5.2.1.4 Increasing number of contract research organizations
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High implementation cost of imaging systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging economies
    • 5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
  • 5.2.4 CHALLENGES
    • 5.2.4.1 High cost of clinical trials
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE PRICING ANALYSIS FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 2021-2023
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS, 2022-2023
• 5.5 TRADE ANALYSIS
  • 5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUS (HS CODE 9022)
    • 5.5.1.1 Import data for X-ray apparatus
    • 5.5.1.2 Export data for X-ray apparatus
  • 5.5.2 TRADE ANALYSIS FOR CT APPARATUS (HS CODE 902212)
    • 5.5.2.1 Import data for CT apparatus
    • 5.5.2.2 Export data for CT apparatus
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 SUPPLY CHAIN ANALYSIS
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 KEY BUYING CRITERIA
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
• 5.13 TECHNOLOGY ANALYSIS
  • 5.13.1 KEY TECHNOLOGIES
    • 5.13.1.1 CT and MRI
  • 5.13.2 COMPLEMENTARY TECHNOLOGIES
    • 5.13.2.1 Ultrasound
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 REVIEW OF CT FINDINGS AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LIVER CARCINOSARCOMA
• 5.16 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL IMAGING MARKET

6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE

• 6.1 INTRODUCTION
• 6.2 SERVICES
  • 6.2.1 OPERATIONAL IMAGING SERVICES
    • 6.2.1.1 Rising number of CROs and growing pharmaceutical industry to drive market
  • 6.2.2 READ ANALYSIS SERVICES
    • 6.2.2.1 Increasing number of clinical trials and rising R&D spending to support market growth
  • 6.2.3 SYSTEM AND TECHNICAL SUPPORT SERVICES
    • 6.2.3.1 Need for continuous technical support to propel segment growth
  • 6.2.4 TRIAL DESIGN AND CONSULTING SERVICES
    • 6.2.4.1 High R&D spending and favorable government initiatives for clinical trials to fuel market growth
• 6.3 SOFTWARE
  • 6.3.1 NEED FOR HIGHLY EFFICIENT AND COST-EFFECTIVE CLINICAL OPERATIONS SOFTWARE TO FAVOR MARKET GROWTH

7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY

• 7.1 INTRODUCTION
• 7.2 COMPUTED TOMOGRAPHY
  • 7.2.1 HIGHER CONTRAST IMAGE AND QUICKER TEST RESULTS TO AUGMENT SEGMENT GROWTH
• 7.3 MAGNETIC RESONANCE IMAGING
  • 7.3.1 GREATER OBJECTIVITY, SENSITIVITY, AND REPRODUCIBILITY TO PROPEL MARKET GROWTH
• 7.4 ULTRASOUND
  • 7.4.1 COST-EFFECTIVENESS AND EASE OF USE TO FUEL MARKET GROWTH
• 7.5 POSITRON EMISSION TOMOGRAPHY
  • 7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS IN HUMANS AND ANIMALS TO BOOST MARKET GROWTH
• 7.6 X-RAY
  • 7.6.1 LOW SCANNING COST AND TECHNOLOGICAL ADVANCEMENTS TO FAVOR MARKET GROWTH
• 7.7 OTHER MODALITIES

8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA

• 8.1 INTRODUCTION
• 8.2 ONCOLOGY
  • 8.2.1 GROWING INCIDENCE OF CANCER AND INCREASING R&D INVESTMENTS BY PHARMA COMPANIES TO AID MARKET GROWTH
• 8.3 INFECTIOUS DISEASES
  • 8.3.1 RISING DRUG DISCOVERY ACTIVITY AND GROWING DEMAND FOR THERAPEUTICS TO SPUR MARKET GROWTH
• 8.4 NEUROLOGY
  • 8.4.1 HIGH RESEARCH INVESTMENTS FOR NEUROLOGIC DRUGS TO PROPEL MARKET GROWTH
• 8.5 CARDIOVASCULAR SYSTEM DISORDERS
  • 8.5.1 HIGH MORTALITY RATE AND COMPLEX CLINICAL TRIAL PROCEDURES TO AUGMENT MARKET GROWTH
• 8.6 ENDOCRINOLOGY
  • 8.6.1 RISING PREVALENCE OF DIABETES AND INCREASING RESEARCH FUNDING FOR METABOLIC DISORDERS TO DRIVE MARKET
• 8.7 IMMUNOLOGICAL DISORDERS
  • 8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
• 8.8 OTHER THERAPEUTIC AREAS

9 CLINICAL TRIAL IMAGING MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.2.1 HIGH R&D BUDGETS AND FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH
• 9.3 MEDICAL DEVICE MANUFACTURERS
  • 9.3.1 HIGH SPENDING ON R&D AND CLINICAL TRIALS TO SUPPORT MARKET GROWTH
• 9.4 CONTRACT RESEARCH ORGANIZATIONS
  • 9.4.1 INCREASING TREND OF OUTSOURCING AND GROWING PATIENT POPULATION IN EMERGING ECONOMIES TO AID MARKET GROWTH
• 9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
  • 9.5.1 RISING RESEARCH FUNDING AND INCREASING GOVERNMENT SUPPORT FOR CLINICAL TRIALS TO BOOST MARKET GROWTH
• 9.6 OTHER END USERS

10 CLINICAL TRIAL IMAGING MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 US to dominate North American clinical trial imaging market during study period
  • 10.2.3 CANADA
    • 10.2.3.1 Increase in per capita healthcare spending to augment market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Strong medical technology infrastructure and increased funding for biomedical research to augment market growth
  • 10.3.3 UK
    • 10.3.3.1 Increased R&D investments and high per capita healthcare expenditure to augment market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Developed generics market and favorable government healthcare policies to support market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Increasing number of drug approvals and rising investments in clinical trials to drive market
  • 10.3.6 SPAIN
    • 10.3.6.1 Increased biologics production and improved healthcare infrastructure to aid market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Favorable government regulations and presence of large target patient population to boost market growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Increasing geriatric population and rising healthcare expenditure to favor market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Increased government focus on developing advanced healthcare infrastructure to augment market growth
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Increasing investments in biopharmaceutical research to propel market growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Developed pharmaceutical and biotechnology industry and high demand for personalized medicines to aid market growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 INCREASED FUNDING AND COLLABORATIONS IN RESEARCH SECTOR TO DRIVE MARKET
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 10.7 GCC COUNTRIES
  • 10.7.1 INCREASING RESEARCH ACTIVITIES AND GROWING BIOTECHNOLOGY INDUSTRY TO SPUR MARKET GROWTH
  • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CLINICAL TRIAL IMAGING MARKET
• 11.3 REVENUE ANALYSIS, 2021-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2023)
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Service & software footprint
    • 11.5.5.3 Therapeutic area footprint
    • 11.5.5.4 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
• 11.8 COMPETITIVE SCENARIO
  • 11.8.1 SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS
  • 11.8.2 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 ICON PLC
    • 12.1.1.1 Business overview
    • 12.1.1.2 Services/Solutions offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Solution launches
      • 12.1.1.3.2 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 MEDPACE
    • 12.1.2.1 Business overview
    • 12.1.2.2 Services/Solutions offered
    • 12.1.2.3 MnM view
      • 12.1.2.3.1 Key strengths
      • 12.1.2.3.2 Strategic choices
      • 12.1.2.3.3 Weaknesses and competitive threats
  • 12.1.3 CLARIO
    • 12.1.3.1 Business overview
    • 12.1.3.2 Services/Solutions offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Solution launches
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 IXICO PLC
    • 12.1.4.1 Business overview
    • 12.1.4.2 Services/Solutions offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Deals
      • 12.1.4.3.2 Other developments
  • 12.1.5 RESONANCE HEALTH LTD.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Services/Solutions offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Service launches and regulatory approvals
      • 12.1.5.3.2 Deals
  • 12.1.6 RADIANT SAGE
    • 12.1.6.1 Business overview
    • 12.1.6.2 Services/Solutions offered
  • 12.1.7 WCG CLINICAL
    • 12.1.7.1 Business overview
    • 12.1.7.2 Services/Solutions offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 CARDIOVASCULAR IMAGING TECHNOLOGIES
    • 12.1.8.1 Business overview
    • 12.1.8.2 Services/Solutions offered
• 12.2 OTHER PLAYERS
  • 12.2.1 MEDICAL METRICS, INC.
  • 12.2.2 PRISM CLINICAL IMAGING
  • 12.2.3 BOSTON IMAGING CORE LAB
  • 12.2.4 ANAGRAM 4 CLINICAL TRIALS
  • 12.2.5 VOIANT
  • 12.2.6 CALYX
  • 12.2.7 BIOSPECTIVE INC.
  • 12.2.8 PROSCAN IMAGING
  • 12.2.9 MICRON, INC.
  • 12.2.10 IMAGING ENDPOINTS
  • 12.2.11 PERSPECTUM
  • 12.2.12 PHARMTRACE
  • 12.2.13 NAVITAS LIFE SCIENCES
  • 12.2.14 MEDIAN TECHNOLOGIES
  • 12.2.15 INVICRO, LLC
  • 12.2.16 IMAGE CORE LAB
  • 12.2.17 IMAGE ANALYSIS GROUP (IAG)

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS